Royalty Pharma and Revolution Medicines Forge $2 Billion Strategic Funding Pact to Accelerate Global Development of RAS Cancer Therapies Royalty Pharma plc, a prominent funder of innovation in the biopharmaceutical industry, announced a transformative agreement with Revolution Medicines, Inc., securing…
Baxter Releases 2024 Corporate Responsibility Report, Underscoring Sustainability, Stakeholder Engagement, and Global Impact Baxter International,a global leader in medical technology, has published its 2024 Corporate Responsibility Report, reaffirming the company’s dedication to creating a positive social, environmental, and economic impact…
Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership. Extending their 16-year collaboration…
Regeneron Unveils Groundbreaking $200 Million Donation Matching Program to Expand Patient Access to Vision-Saving Treatments Regeneron Pharmaceuticals, a leader in biotechnology and a longtime advocate for equitable healthcare access, has announced a bold new philanthropic initiative designed to support patients…
Aetna Champions Industry-Wide Push to Streamline Prior Authorization and Improve Patient-Centered Health Care Experience Aetna, a CVS Health company, has publicly announced its strong support for a series of transformative healthcare initiatives aimed at improving both patient and provider experiences—chief…
Vertex and Ono Pharmaceutical Forge Strategic Partnership to Develop and Commercialize Povetacicept in Japan and South Korea In a move that underscores the growing international collaboration in advancing treatment for autoimmune and kidney-related diseases, Vertex Pharmaceuticals Incorporated and Ono Pharmaceutical…
Amgen Unveils Full Phase 2 Data on Monthly Obesity Drug MariTide, Highlighting Robust Weight Loss and Cardiometabolic Benefits at ADA 2024 Amgen has presented comprehensive results from the first part of its Phase 2 clinical trial investigating MariTide (formerly AMG…
Datroway Gains Accelerated FDA Approval for Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Datroway (datopotamab deruxtecan, also referred to as Dato-DXd) for the treatment of adult patients…
Merck’s WINREVAIR Achieves Primary Endpoint in Phase 3 HYPERION Trial for Pulmonary Arterial Hypertension in Newly Diagnosed Adults Merck, operating as MSD outside the United States and Canada, has announced a significant clinical milestone in its ongoing commitment to improving…
Novo Nordisk Secures EU CHMP Backing for Ozempic® Label Expansion in PAD, Reinforcing Semaglutide’s Role in Managing Type 2 Diabetes with Comorbidities Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)…
Exelixis Reports Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combo in Metastatic Colorectal Cancer Exelixis, has announced promising topline results from the STELLAR-303 phase 3 pivotal clinical trial, a major milestone in the development of its investigational therapy zanzalintinib.…
Sarclisa Moves Closer to EU Approval for Frontline Treatment of Transplant-Eligible Multiple Myeloma Patients The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Sarclisa (isatuximab) in combination with…
